Key Takeaway
GLP-1 medications have made headlines for weight loss. But the GLP-1 cardiovascular benefits may be even more significant. A landmark clinical trial showed that semaglutide reduced major heart events) heart attacks, strokes, and cardiovascular death (by 20%[1].
GLP-1 medications have made headlines for weight loss. But the GLP-1 cardiovascular benefits may be even more significant. A landmark clinical trial showed that semaglutide reduced major heart events) heart attacks, strokes, and cardiovascular death (by 20%[1]. And this benefit appeared to be independent of weight loss alone.
Key Takeaways: - The SELECT Trial[1]: A significant step for Cardiology - Discover why glp-1 medications help the heart - Who Should Consider GLP-1 Treatment for Heart Health - Beyond SELECT: Other Cardiovascular Evidence
For the millions of Americans living with both obesity and heart disease risk, this changes the conversation. GLP-1 medications are no longer just weight loss drugs. They may be some of the most important cardiovascular medications developed in the last decade. Here is what the research shows and what it means for you.
The SELECT Trial: A significant step for Cardiology
The SELECT trial is the study that put GLP-1 cardiovascular benefits on the map. It was a massive randomized, double-blind, placebo-controlled trial) the gold standard of medical research. Over 17,600 adults with established cardiovascular disease and obesity (but without diabetes) participated.
Participants received either semaglutide 2.4 mg weekly or placebo for a mean follow-up of about 40 months. The primary endpoint was MACE (major adverse cardiovascular events, which includes cardiovascular death, nonfatal heart attack, and nonfatal stroke.
The results were striking. Semaglutide reduced MACE by 20% compared to placebo. for every 100 heart events expected in the placebo group, only 80 occurred in the semaglutide group. The effect was consistent across subgroups regardless of age, sex, race, or baseline BMI.
What made this trial particularly notable was the population studied. These were people with established heart disease but without diabetes. Previous cardiovascular outcome trials for GLP-1 medications had been conducted in people with type 2 diabetes. SELECT showed that the heart benefits extend beyond the diabetic population.
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
The trial also showed reductions in individual components of MACE. Heart attack risk dropped. Stroke risk dropped. Cardiovascular death trended lower. And these benefits emerged relatively early in the trial (within the first year for some endpoints.
Free Download: GLP-1 Medication Comparison One-Pager See how each GLP-1 medication stacks up on cardiovascular outcomes, weight loss, and more) all in one quick-reference chart. Get yours free (we'll email it to you instantly. [Download Now]
Why GLP-1 Medications Help the Heart
The cardiovascular benefits of GLP-1 medications appear to come from multiple mechanisms) not just weight loss.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Reducing inflammation. Chronic inflammation drives atherosclerosis, the buildup of plaque in arteries that leads to heart attacks and strokes. GLP-1 receptor agonists have been shown to reduce C-reactive protein (CRP) and other inflammatory markers. In the SELECT trial, semaglutide reduced CRP by approximately 38%. This anti-inflammatory effect may be one of the most important pathways for heart protection.
Improving blood lipids. GLP-1 medications can improve cholesterol profiles by reducing triglycerides and, in some cases, LDL cholesterol. Better lipid profiles mean less plaque buildup in your arteries over time.
Lowering blood pressure. Studies consistently show that GLP-1 agonists modestly reduce systolic blood pressure (typically by 3-5 mmHg. While that may sound small, at a population level, even modest blood pressure reductions translate into significant reductions in heart events.
Reducing visceral fat. Not all body fat carries the same risk. Visceral fat) the fat around your organs (is strongly linked to cardiovascular disease. GLP-1 medications preferentially reduce visceral fat, which may explain why their heart benefits extend beyond what weight loss alone would predict.
Direct vascular effects. GLP-1 receptors are found on blood vessel walls and heart tissue. Activating these receptors may directly improve blood vessel function and protect the heart muscle from damage.
This multi-pronged approach is why researchers believe the cardiovascular benefits go beyond simple weight reduction. Your heart benefits from less inflammation, better blood flow, lower pressure, and reduced metabolic stress all at once.
Want to learn more about how GLP-1 medications work? Read our .
Who Should Consider GLP-1 Treatment for Heart Health
Based on the SELECT trial and other cardiovascular outcome data, GLP-1 medications may be especially beneficial for certain groups.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →People with established cardiovascular disease and obesity. This is the exact population studied in SELECT. If you have had a heart attack, stroke, or have known atherosclerotic disease and also have a BMI of 27 or higher, the evidence for GLP-1 treatment is strong.
People with multiple cardiovascular risk factors. Even without established heart disease, if you have obesity plus high blood pressure, high cholesterol, or a strong family history of heart events, GLP-1 treatment may reduce your overall risk.
People with type 2 diabetes and heart disease risk. Multiple cardiovascular outcome trials) SUSTAIN 6[2], LEADER, and others (have shown that GLP-1 medications reduce heart events in people with type 2 diabetes. If you have both conditions, the benefits are well-documented.
People who haven't responded to lifestyle changes alone. If diet and exercise haven't been enough to manage your weight and cardiovascular risk factors, adding a GLP-1 medication may provide the additional support you need.
Your provider will consider your complete health picture. A FormBlends consultation includes a thorough review of your medical history, current medications, and risk factors. If you're concerned about heart health and weight management, is the right first step. You can also to see if GLP-1 treatment may be appropriate for you.
Beyond SELECT: Other Cardiovascular Evidence
The SELECT trial is the most headline-grabbing study, but it builds on a foundation of earlier research.
The SUSTAIN 6 trial showed that semaglutide reduced MACE by 26% in people with type 2 diabetes and high cardiovascular risk. The LEADER trial (Marso et al., NEJM, 2016) showed liraglutide reduced MACE by 13% in a similar population. The REWIND trial (Gerstein et al., Lancet, 2019) showed dulaglutide reduced MACE by 12%.
A pattern emerges across all of these trials: GLP-1 receptor agonists consistently reduce cardiovascular events. The effect isn't specific to one drug in the class. It appears to be a class-wide benefit.
More recently, researchers have been examining whether the cardiovascular benefits extend to dual-agonist medications like tirzepatide. The SURPASS-CVOT trial is testing tirzepatide's cardiovascular outcomes. Based on tirzepatide's superior metabolic effects, many researchers expect positive cardiovascular results, but the data isn't yet available.
For now, the evidence is clearest for semaglutide and liraglutide. If cardiovascular protection is a priority for you, these medications have the strongest published data. Compare your options with our or view to see what treatment may cost.
Frequently Asked Questions
Can GLP-1 medications prevent heart attacks?
Clinical trials suggest GLP-1 medications can significantly reduce the risk of heart attacks in people with obesity and established cardiovascular disease. The SELECT trial showed a 20% reduction in major heart events with semaglutide. But no medication eliminates heart attack risk entirely. GLP-1 treatment should be part of a full cardiovascular[1] care plan.
Do GLP-1 cardiovascular benefits depend on weight loss?
Research suggests the heart benefits go beyond weight loss alone. In the SELECT trial, cardiovascular event reduction appeared early) before maximum weight loss occurred (and analyses suggest the benefit was partly independent of the amount of weight lost. Anti-inflammatory effects and improved blood vessel function may play significant roles.
Is semaglutide approved for heart disease?
Semaglutide has received an expanded indication for reducing cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. This was based on the SELECT trial results. Your provider can determine whether this indication applies to your situation.
How long do I need to take GLP-1 medication for heart benefits?
Cardiovascular benefits in clinical trials were observed with continued treatment over several years. In the SELECT trial, benefits emerged within the first year and continued to accumulate over the study period. Most providers recommend long-term use for sustained cardiovascular protection. Your provider will create a plan based on your individual needs.
Can I take GLP-1 medication if I already take heart medications?
GLP-1 medications can generally be used alongside common cardiovascular medications like statins, blood pressure drugs, and blood thinners. Your provider will review your complete medication list to ensure there are no interactions. Always disclose all medications during your consultation.
Start your goals Today
Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you) consultations are free and confidential.
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[6] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[7] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[8] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24